Top considerations when determining whether to approve expensive drugs March 30, 2017 By Bryant Furlow Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations. Expedited FDA approval plays dominant role in drug approvals March 30, 2017 By Bryant Furlow Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017. Opinion: More industry-stakeholders play blame game for high drug costs March 23, 2017 By Devon Herrick PhD Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs. How data analytics combats the opioid epidemic Deaths due to opioid abuse have risen sharply—and show no signs of leveling off. Here’s how data analytics can prevent abuse and diversion. Predictions for biosimilars: How market access will play out Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars. Antidepressant drug pipeline: What to know August 29, 2016 By Erin Bastick There are promising developments in the pipeline for patients with treatment-resistant depression. Top 4 pharmacy trends healthcare executives should watch August 28, 2016 By Karen Appold Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results. Cardiovascular drugs: Current spending, future outlook May 06, 2016 By Tracey Walker Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population. Pharma coupons: pros and cons May 04, 2016 By Mari Edlin Drug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed. Impact of Medicare's expanded benzodiazepine coverage Like any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications—just a year after Medicare Part D extended its coverage to include them in 2012—has some wondering why so many of these drugs are being prescribed.